A Science study found that recurrent mutations in the promoter of the telomerase gene, TERT, could be responsible for overexpression of telomerase in a majority of cancers, thereby sustaining the ...

“ Clinician feedback, in addition to the Trust 2 Study results, suggests that the TERT promoter mutation add-on assay has limited impact on decision-making when evaluating pigmented lesions for ...